|

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

RECRUITINGSponsored by Dong-A ST Co., Ltd.
Actively Recruiting
SponsorDong-A ST Co., Ltd.
Started2021-02-08
Est. completion2031-12
Eligibility
Age2 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04798690

Summary

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.

Eligibility

Age: 2 Years+Healthy volunteers accepted
Inclusion Criteria:

* Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
* Children who has official height record at least 6 months prior

Exclusion Criteria:

* Children with Epiphyseal closure

Conditions5

Growth Hormone DeficiencyHeart DiseaseIdiopathic Short StatureSmall for Gestational AgeTurner Syndrome

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.